Partner Headlines - ESRX

  1. Will Bill Ackman Go After Express Scripts Next?

    GuruFocus
  2. Acquisitions May Fuel Gilead Sciences' Winning Ways

    IBD
  3. Horizon Pharma Seen In Deal-Making Mode

    IBD
  4. McKesson Sees Healthy Growth In Prescription Drugs

    IBD
  5. David Rolfe Adds to Most Valuable Stakes in His Portfolio

    GuruFocus
  6. Regeneron/Sanofi Cholesterol Drug Wins FDA Panel Vote

    IBD
  7. Gilead Nears Buy Zone On Healthy Drug Trial Results

    IBD
  8. Why Diplomat Pharmacy Gains Since IPO Look So Healthy

    IBD
  9. Horizon Pharma Survives Through Transformation

    IBD
  10. Morning Market Losers

    Benzinga
  11. Benzinga's Top Downgrades

    Benzinga
  12. Raymond James Downgrades Express Scripts Holding To Market Perform

    Benzinga
  13. Dodge & Cox Keeps Buying Express Scripts

    GuruFocus
  14. Pay-For-Performance Medicine

    Benzinga
  15. Making Money With Charles Payne: 05/26/15

    FoxBusiness
  16. Horizon Pharma Up On Bullish Leerink Initiation

    IBD
  17. CVS Health Buys Omnicare, Citing 'Long-Term' Benefits

    IBD
  18. Drug 'super spending' soars

    IBD
  19. 20 Questions With David Rolfe Part I

    GuruFocus
  20. Addiction Care Provider AAC Eyes National Brand

    IBD
  21. Medivation, Jazz Q1 Reports Miss; Regeneron Beats

    IBD
  22. Regeneron Q1 Earnings Beat As Eylea Research Pays Off

    IBD
  23. GoPro, Other Earnings Trigger Wild Price Swings

    IBD
  24. EXPRESS SCRIPTS

    IBD
  25. Express Scripts Posts In-Line Q1 Earnings, Issues Strong Forecast

    Benzinga
  26. Stocks Stumble To Early Losses; IPG Photonics Jumps

    IBD
  27. Why CVS Health And McKesson May Be Good Stock Picks

    IBD
  28. UnitedHealth Profit Soars On ObamaCare, Optum

    IBD
  29. UnitedHealth Up After Topping Views, Raising Outlook

    IBD
  30. UnitedHealth Eyes Biggest Earnings Gain In Years

    IBD
  31. Pioneer Fundamental Growth Fund: Why Is It Revving Up?

    IBD
  32. Horizon Pharma Soars On Q4 Beat, Guidance Raise

    IBD
  33. Catamaran EPS Tops, But Stock Falls On Weak Guidance

    IBD
  34. 10 Stocks You Should Be Watching Today

    Benzinga
  35. EXPRESS SCRIPTS

    IBD
  36. UPDATE: Express Scripts Tops Q4 Expectations, Shares Rise After ...

    Benzinga
  37. Nasdaq Stretches Win Streak To 9 Days

    IBD
  38. Earnings Scheduled For February 23, 2015

    Benzinga
  39. Must Watch Stocks for Today

    Benzinga
  40. Stocks Cap Short Week With Gains; Salix Up On Buyout Hopes

    IBD
  41. Rolfe Adds One Company to Portfolio in Fourth Quarter

    GuruFocus
  42. Analyzing Needham Growth Fund's Pick: Express Scripts (ESRX)

    GuruFocus
  43. Analyzing Needham Growth Fund's Pick: CarMax (KMX)

    GuruFocus
  44. Rite Aid Stock Soars, Steps Up Competition With CVS

    IBD
  45. Gilead Sciences Offering Fresh Wave Of Competition To AbbVie's ...

    GuruFocus
  46. Thornburg Value Fund Q4 2014 Commentary

    GuruFocus
  47. Gilead Q4 Earnings Beat, But Price War Taking Toll

    IBD
  48. Baird Remains Buyers Of Gilead Before Earnings Release

    Benzinga
  49. Cramer Gives His Opinion On Whole Foods Market, Whiting Petroleum ...

    Benzinga
  50. AmerisourceBergen Hits New High On Earnings, Outlook

    IBD
  51. Has Gilead Sciences Been Able To Maintain Its Lead Run In The ...

    GuruFocus
  52. Gilead, AbbVie Hepatitis C Price Cuts Will Hit Sales

    IBD
  53. Why Drug Pricing Could Bring Volatility To The Biotech Sector ...

    Benzinga
  54. Aetna Sides With Gilead In Hepatitis C Drug Battle

    IBD
  55. What The Market's Reading: An Iraq Ramp-Up & Biotech Moves

    Benzinga
  56. Steven Romick Buys 7 US and International Stocks in Q4

    GuruFocus
  57. Express Scripts Eyes New Price War: Anti-PCSK9 Drugs

    IBD
  58. Cholesterol Drug Costs Eyed

    IBD
  59. AbbVie Inc.'s Forthcoming Future Looks Optimistic

    GuruFocus
  60. Amgen's Decline May Be Linked To Comments Of Express Script's ...

    Benzinga
  61. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  62. AbbVie Stock Down After Guidance, Downgrade

    IBD
  63. Gilead Strikes Deal with CVS, Hits Back AbbVie

    GuruFocus
  64. Hepatitis Drugs Vie For Share

    IBD
  65. CVS Covering Gilead HCV Drugs, Countering AbbVie

    IBD
  66. Stocks Lose More Ground; Gilead Sciences Rises

    IBD
  67. CVS Picks Gilead Hep C Drugs As Price War Looms

    IBD
  68. Drug Distributor Reaps The Rewards Of Strategy Shift

    IBD
  69. Express Scripts Stock Dominated Q4; Which Funds Might've Won?

    Benzinga
  70. 5 Biotech Stocks With Big News Due In January

    IBD
  71. Stocks Hold Near Highs; LifeLock Breaks Out

    IBD
  72. Facebook Among IBD 50's Top 5 Earnings Kings In 2014

    IBD
  73. IBD 50: Biotechs Hammered, Then Find Support

    IBD
  74. First Pacific Advisors' Third-Quarter Investment in Yahoo! Increases ...

    GuruFocus
  75. Biotech Stocks Take A Beating, But Find Support

    IBD
  76. Stocks Score Small Gains; Virgin America Takes Flight

    IBD
  77. How Gilead And Johnson & Johnson's Tumble Affected These Hedge ...

    Benzinga
  78. Evercore ISI Analyst: 160,000 Patients Affected by AbbVie Hepatitis ...

    Benzinga
  79. Toys, Department Stores Rock, But Biotechs Tumble

    IBD
  80. Deutsche Bank Analyst Sees Gilead Sciences Vs. AbbVie 'Price ...

    Benzinga
  81. AbbVie Drug Displaces Gilead

    IBD
  82. Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive

    IBD
  83. Express Scripts Picks AbbVie HCV Drugs Over Gilead

    IBD
  84. Express Scripts Knocks Gilead's Hepatitis C Drug in Favor of ...

    GuruFocus
  85. Bank Of America Downgrades Gilead Sciences, Sees Possible Pricing ...

    Benzinga
  86. Broad Indexes Little Changed; Facebook Breaks Out

    IBD
  87. Dow Outperforms While Nasdaq Holds Small Gain; Oil Weak

    IBD
  88. Express Scripts Picks AbbVie HCV Drugs Over Gilead

    IBD
  89. Mid-Morning Market Update: Markets Open Higher; Caesars Entertainment ...

    Benzinga
  90. Stocks Struggle To Hold Gains; Alaska Air, Spirit Up

    IBD
  91. Gilead Sciences Plummets Amid AbbVie Deal With Express Scripts

    Benzinga
  92. Stock Futures Point Higher; AbbVie Surges, Gilead Dives

    IBD
  93. AbbVie's Hep C Regimen OK'd, 12-Week Cost $83,319

    IBD
  94. How Can Drugmakers Handle New Pricing Pressures?

    IBD
  95. Are These Drugstore Retailers Good Investments?

    GuruFocus
  96. AmerisourceBergen a Key Player in the Pharma Industry

    GuruFocus
  97. Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI

    GuruFocus
  98. 5 Stock-Moving Medtech Events This December

    IBD
  99. Top 4 Stocks In The Health Care Plans Industry With The Highest ...

    Benzinga
  100. Surprisingly, Warren Buffett Buys These 8 Dividend Stocks

    GuruFocus
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!